Printer Friendly

Sangart begins Phase Ib study of MP4CO.

M2 PHARMA-January 13, 2012-Sangart begins Phase Ib study of MP4CO(C)2012 M2 COMMUNICATIONS

13 January 2012 - Sangart Inc, a US-based biopharmaceutical company specialising in oxygen-therapeutic agents, said on Thursday that it had launched a Phase Ib trial aimed at assessing the safety of MP4CO treatment in patients with sickle cell disease.

MP4CO is a compound designed to deliver therapeutic levels of carbon monoxide (CO) to patients suffering from a sickle cell crisis.

The study will involve patients who have not suffered from a painful vaso-occlusive crisis. Preclinical studies show that carbon monoxide leads to stabilisation of the haemoglobin levels of patients with sickle cell disease and prevents the sickling of red blood cells.

The trial will be conducted at four sites in the UK, France and Jamaica. The primary endpoint of the study is to evaluate the safety of treatment with MP4CO.

((Comments on this story may be sent to

COPYRIGHT 2012 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jan 13, 2012
Previous Article:Urologix agrees on USD2m credit line.
Next Article:Walgreens board announces USD0.225 p/s quarterly dividend.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters